These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 6879005)

  • 61. Measles outbreak in the Ukraine, 2005-2006.
    Spika JS; Aidyralieva C; Mukharskaya L; Kostyuchenko NN; Mulders M; Lipskaya G; Emiroglu N
    Euro Surveill; 2006 Mar; 11(3):E060309.1. PubMed ID: 16804226
    [No Abstract]   [Full Text] [Related]  

  • 62. Antibody response and clinical reactions in children given measles vaccine with immunoglobulin.
    Lingam S; Miller CL; Clarke M; Pateman J
    Br Med J (Clin Res Ed); 1986 Apr; 292(6527):1044-5. PubMed ID: 3083994
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immediate reactions following live attenuated measles vaccine.
    Van Asperen PP; McEniery J; Kemp AS
    Med J Aust; 1981 Oct; 2(7):330-1. PubMed ID: 7300775
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Measles immunization with further attenuated heat-stable measles vaccine using five different methods of administration.
    Kok PW; Kenya PR; Ensering H
    Trans R Soc Trop Med Hyg; 1983; 77(2):171-6. PubMed ID: 6868097
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Epidemiology of measles (author's transl)].
    Fara GM
    Ann Sclavo; 1979 Jun; 21 Suppl 1():384-93. PubMed ID: 42364
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CLINICAL AND SEROLOGICAL OBSERVATIONS ON THE CHILDREN GIVEN ATTENUATED MEASLES VACCINE.
    ARAI M; NAKAMURA M; AKAMATSU T; KIMURA M; KITAYAMA T; KOIDE G
    Acta Paediatr Jpn; 1963 Dec; 14():9-16. PubMed ID: 14200614
    [No Abstract]   [Full Text] [Related]  

  • 67. The specific prevention of measles in Romania. Study of a vaccine prepared in human diploid cells.
    Cepleanu M; Cajal N; Cernescu C; Sorodoc Y; Aderca I; Tigăeru N; Suciu D; Manu S; Ferra A; Biberimoroianu S; Dobrescu A; Lucian M
    Rev Roum Virol (1972); 1973; 10(1):8-17. PubMed ID: 4709858
    [No Abstract]   [Full Text] [Related]  

  • 68. [Clinical and serological studies with a live further attenuated measles vaccine (Moraten) in Chile].
    Ristori C; Boccardo H; Borgoño JM; Greiber R; Heras E; Carrillo B; Solari G; Concha F
    Rev Med Chil; 1970 Jan; 98(1):42-5. PubMed ID: 4157374
    [No Abstract]   [Full Text] [Related]  

  • 69. [Influence of measles vaccination using the live measles virus vaccine SSW-L 16 on the complication rate in measles].
    Heidel G; Olbricht H; Ely K; Henkler J
    Z Arztl Fortbild (Jena); 1972 Feb; 66(3):171-4. PubMed ID: 5047088
    [No Abstract]   [Full Text] [Related]  

  • 70. Analysis of a measles epidemic; possible role of vaccine failures.
    Rawls WE; Rawls ML; Chernesky MA
    Can Med Assoc J; 1975 Nov; 113(10):941-4. PubMed ID: 1192310
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Revaccination of previous recipients of killed measles vaccine: clinical and immunologic studies.
    Krause PJ; Cherry JD; Naiditch MJ; Deseda-Tous J; Walbergh EJ
    J Pediatr; 1978 Oct; 93(4):565-71. PubMed ID: 702235
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children.
    Kanesaki T; Baba K; Tsuda N; Yabuuchi H; Yamanishi K; Takahashi M
    Biken J; 1986 Dec; 29(3-4):63-71. PubMed ID: 3304276
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [High-potency live attenuated measles virus vaccine. Clinical results of Schwarz vaccine].
    Fujii Y; Minamitani M; Nakamura K; Shinozaki T; Nagahama H
    Nihon Ishikai Zasshi; 1969 Mar; 61(5):595-601. PubMed ID: 4890864
    [No Abstract]   [Full Text] [Related]  

  • 74. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial.
    Dilraj A; Cutts FT; de Castro JF; Wheeler JG; Brown D; Roth C; Coovadia HM; Bennett JV
    Lancet; 2000 Mar; 355(9206):798-803. PubMed ID: 10711928
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Outbreak of measles in Belarus, January-June 2006.
    Samoilovich EO; Yermalovich MA; Semeiko GV; Svirchevskaya EI; Rimzha MI; Titov LP
    Euro Surveill; 2006 Jul; 11(7):E060727.3. PubMed ID: 16966769
    [No Abstract]   [Full Text] [Related]  

  • 76. Clinical evaluation of a new measles-mumps-rubella trivalent vaccine.
    Schwarz AJ; Jackson JE; Ehrenkranz NJ; Ventura A; Schiff GM; Walters VW
    Am J Dis Child; 1975 Dec; 129(12):1408-12. PubMed ID: 128287
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Further-attenuated measles vaccine: characteristics and use.
    Krugman S
    Rev Infect Dis; 1983; 5(3):477-81. PubMed ID: 6879002
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Duration of immunity following immunization with live measles vaccine: 15 years of observation in Zhejiang Province, China.
    Dai B; Chen ZH; Liu QC; Wu T; Guo CY; Wang XZ; Fang HH; Xiang YZ
    Bull World Health Organ; 1991; 69(4):415-23. PubMed ID: 1934235
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antibody persistence in Gambian children after high-dose Edmonston-Zagreb measles vaccine.
    Whittle HC; Campbell H; Rahman S; Armstrong JR
    Lancet; 1990 Oct; 336(8722):1046-8. PubMed ID: 1977029
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Live measles vaccine: a 21 year follow up.
    Miller C
    Br Med J (Clin Res Ed); 1987 Jul; 295(6589):22-4. PubMed ID: 3113599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.